Rezafungin
2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium
Molecular Identity
Rezafungin
2-[[(3S,6S,9S,11R,15S,18S,20R,21R,24S,25S,26S)-6-[(1S,2S)-1,2-dihydroxy-2-(4-hydroxyphenyl)ethyl]-11,20,25-trihydroxy-3,15-bis[(1R)-1-hydroxyethyl]-26-methyl-2,5,8,14,17,23-hexaoxo-18-[[4-[4-(4-pentoxyphenyl)phenyl]benzoyl]amino]-1,4,7,13,16,22-hexazatricyclo[22.3.0.09,13]heptacosan-21-yl]oxy]ethyl-trimethylazanium
PubChem CID: 78318119
Rezafungin is a member of the family of echinocandins that inhibits 1,3-beta-D-glucan synthase. It is developed by Cidara Therapeutics and approved for the treatment of candidaemia and invasive candidiasis in patients aged 18 years who have limited or no alternative treatment options. It is a homodetic cyclic peptide, a quaternary ammonium ion, an aromatic ether, an azamacrocycle, an echinocandin and an antibiotic antifungal drug.
2D Structure
Properties
C63H85N8O17+
Molecular Formula
1226.40
Molecular Weight
g/mol
1225.6033
Exact Mass
Da
2.9
XLogP
Drug-like (Lipinski: < 5)
366
TPSA
May have limited oral absorption
13
H-Bond Donors
17
H-Bond Acceptors
2300
Complexity
SMILES
Canonical SMILES
SMILES: Synonyms(20)
Rezafungin1396640-59-7Rezafungin ionRezafungin cationBiafunginCD101CD-101SP-3025REZZAYOG013B5478JRefChem:582321631754-41-0Rezafungin?REZAFUNGIN [WHO-DD]orb1309158
Data from PubChem (NCBI)
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Drug Network
Trials and conditions connected to Rezafungin
Loading drug network...